The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Open accessAbstract
Antibody therapies to prevent or limit filovirus infections have received modest interest in recent years, in part because of early negative experimental evidence. We have overcome the limitations of this approach, leveraging the use of antibody from nonhuman primates (NHPs) that survived challenge to filoviruses under controlled conditions. By using concentrated, polyclonal IgG antibody from these survivors, we treated filovirus-infected NHPs with multiple doses administered over the clinical phase of disease. In the first study, Marburg virus (MARV)-infected NHPs were treated 15 to 30 min postexposure with virus-specific IgG, with additional treatments on days 4 and 8 postexposure. The postexposure IgG treatment was completely protective, with no signs of disease or detectable viremia. MARV-specific IgM antibody responses were generated, and all macaques survived rechallenge with MARV, suggesting that they generated an immune response to virus replication. In the next set of studies, NHPs were infected with MARV or Ebola virus (EBOV), and treatments were delayed 48 h, with additional treatments on days 4 and 8 postexposure. The delayed treatments protected both MARV- and EBOV-challenged NHPs. In both studies, two of the three IgG-treated NHPs had no clinical signs of illness, with the third NHP developing mild and delayed signs of disease followed by full recovery. These studies clearly demonstrate that postexposure antibody treatments can protect NHPs and open avenues for filovirus therapies for human use using established Food and Drug Administration-approved polyclonal or monoclonal antibody technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques
Geisbert, T. W., Hensley, L. E., Larsen, T., Young, H. A., Reed, D. S., Geisbert, J. B., Scott, D. P., Kagan, E., Jahrling, P. B., & Davis, K. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63591-2 · Cited by 576
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K. (2000) · Science · doi:10.1126/science.287.5458.1664 · Cited by 459
Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients
Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., Colebunders, R., Muyembe‐Tamfum, J. J., & the International Scientific and Technical Committee (1999) · The Journal of Infectious Diseases · doi:10.1086/514298 · Cited by 420
Geisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., & Vlasuk, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15012-x · Cited by 382
Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.
(1978) · Europe PMC (PubMed Central) · Cited by 325
Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W. H. I., & Burton, D. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.6024-6030.1999 · Cited by 293
Effective Post-Exposure Treatment of Ebola Infection
Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030002 · Cited by 288
Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Cited by
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 610
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.4218 · Cited by 324
Metadata
- Authors
- Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-03-12
- Volume
- 109
- Issue
- 13
- Pages
- 5034-5039
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2028463307
- Cited by
- 268
- References
- 25
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. https://app.cochat.ai/papers/10.1073/pnas.1200409109
- The paper
- Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D. (2012). Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1200409109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.